Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Myovant Sciences Ltd.

Division of Roivant Sciences Inc.
www.myovant.com

Latest From Myovant Sciences Ltd.

Sunovion Plans September Launch For Parkinson’s 'Off' Episode Drug Kynmobi

Kynmobi is an important approval for parent company Sumitomo Dainippon ahead of the loss of exclusivity for Latuda. Sunovion hopes to launch after COVID-19 social distancing requirements ease.

Approvals Neurology

Can Zydus Cadila's Cut-Price Enzalutamide Shake Up Indian Market?

Cadila Healthcare has launched a generic version of Astellas/Pfizer’s prostate cancer therapy Xtandi in India at a sharp discount of 70-90% to existing brands and hopes the lower financial burden on patients will aid adherence.

Commercial Business Strategies

Keeping Track Of Submissions: Myovant’s First Relugolix NDA; Merck Resubmits Longer Keytruda Dosing; Biogen Adjusts Aducanumab Rolling Target

The latest news and highlights about submissions for US approval, from the Pink Sheet FDA Performance Tracker.

US FDA Performance Tracker Drug Review

Myovant's Relugolix Shows Promising Profile For Endometriosis Pain

The first Phase III trial testing relugolix combination therapy in endometriosis pain showed efficacy with minimal bone mineral density loss, an issue with AbbVie's rival drug Orilissa. An US NDA was also filed in prostate cancer.

Clinical Trials Gynecology & Urology
See All

Company Information

  • Industry
  • Biotechnology
    • Antisense, Oligonucleotides
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Gynecological, Urological
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Company Type
  • Start-Up
  • Parent & Subsidiaries
  • Roivant Sciences Inc.
  • Senior Management
  • Lynn Seely, MD, CEO
    Frank Karbe, Pres. & CFO
    Kim Sablich, Chief Commercial Officer
    Juan Camilo Arjona Ferreira, MD, CMO
  • Contact Info
  • Myovant Sciences Ltd.
    Phone: (650) 238-0250
    2000 Sierra Point Pkwy.
    9th Floor
    Brisbane, CA 94005
    USA
UsernamePublicRestriction

Register